Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 | |||
By: GlobeNewswire - 10 Apr 2024 | Back to overview list |
||
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
Cambridge, UK, 10 April 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted immune cell enhancing therapeutics, has presented preclinical data at the 2024 American Association for Cancer Research (AACR) Annual Meeting on its two leading programmes:
These programmes are derived from Crescendo’s proprietary Humabody® VH platform which is associated with superior tumour penetration compared to traditional antibodies. Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer. The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients. “The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial. CB699 is a pipeline programme which has excited us with its potential and I am delighted that we have been able to share our early research at this year’s conference. These preclinical findings support this candidate’s progression into clinical development, and we look forward to providing further insights as the programme matures.” Abstract #5313: CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumours The details of this research have also been published in Clinical Cancer Research, a journal of the AACR. The paper, ‘CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumours’, co-authored by Crescendo scientists and Regius Professor of Cancer Research, Johann de Bono from The Institute of Cancer Research, London, reports:
Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, comments: “The data shared at AACR and published in Clinical Cancer Research support this novel candidate’s (CB307) clinical evaluation in PSMA+ mCRPC, both as a monotherapy and in combination settings.” Abstract #5302: CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumours
Both abstracts are available on the AACR website and the posters are available on the Crescendo website under Posters & Publications. -Ends- For more information, please contact:
About CB307 CB307 conditionally activates only tumour-specific T cells, exclusively within the tumour microenvironment, using the CD137 co-stimulatory mechanism. Its unique format enables potent, tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA+ cancer indications to address a large unmet medical need. Clinical development of CB307 is on track with the Phase 1b POTENTIA trial ongoing in adult patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). POTENTIA (NCT04839991) is an open-label, dose escalation and cohort expansion study to assess the safety, tolerability and preliminary efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). About CB699 About Crescendo Biologics |
|||
|
|||
Copyright 2024 GlobeNewswire | Back to overview list |